Journal of Pediatric Health Care
Volume 22, Issue 1 , Pages 52-59 , January 2008

Practice Guideline for Diagnosis and Management of Migraine Headaches in Children and Adolescents: Part Two

References 

  1. Alecrim-Andrade J, Maciel-Junior JA, Cladelleas XC, Correa-Filho HR, Machado HC. Acupuncture in migraine prophylaxis; A randomized sham-controlled trial. Cephalalgia. 2006;26:520–529
  2. Ashkenazi A, Silberstein D. Hormone-related headache: Pathophysiology and treatment. CNS Drugs. 2006;20:125–141
  3. Birmaher, B., & Brent, D. (2007). American Academy of Child and Adolescent Psychiatry: Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. Retrieved September 26, 2007, from www.aacap.org/galleries/Practice Parameters/InPress_2007_DepressiveDisorders.pdf
  4. Borsook D, Burstein R, Moulton E, Becerra L. Functional imaging of the trigeminal system: Applications to migraine pathophysiology. Headache: The Journal of Face and Pain. 2006;46:S32–S38
  5. Dafer, R., & Birbeck, G. (2006). Migraine variants. Retrieved July 24, 2007, from http://www.emedicine.com/NEURO/topic219.htm
  6. Damen L, Bruijn KJ, Verhagen AP, Berger MY, Passchier J, Koes BW. Symptomatic treatment of migraine in children: A systematic review of medication trials. Pediatrics. 2005;116:295–302
  7. Damen L, Bruijn J, Koes BW, Berger MY, Passchier J, Verhagen AP. Prophylactic treatment of migraine in children (Part 1: A systematic review of non-pharmacological trials). Cephalalia. 2006;26:373–383
  8. Damen L, Bruijn J, Verhagen AP, Berger MY, Passchier J, Koes BW. Prophylactic treatment of migraines in children (Part 2: A systematic review of pharmacological trials). Cephalgia. 2006;26:497–504
  9. Diener HC, Pfaffenrath V, Schnitker J, Griede M, Henneike-von Zepelin H-H. Efficacy and safety of 6.25 mg. t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention—a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia. 2005;25:1031–1041
  10. Gunner KB, Smith HD. Practice guideline for the diagnosis and management of migraine headaches in children and adolescents: Part One. Journal of Pediatric Health Care. 2007;21:327–332
  11. Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S. Practice parameter: Pharmacological treatment of migraine headache in children and adolescents. Neurology. 2004;63:2215–2224
  12. Lewis DL, Yonker M, Winner P, Sowell M. The treatment of pediatric migraine. Pediatric Annals. 2005;34:449–460
  13. Linder SL. A practical approach to pediatric headaches. May Paper presented at the Pediatric Nursing Clinical and Professional Update “Care for Kids” Conference. Dallas, TX: Greater Texas Chapter National Association of Pediatric Nurse Practitioners and El Centro College; 2006;
  14. Powers SW, Andrasik F. Biobehavioral treatment, disability, and psychological effects of pediatric headache. Pediatric Annals. 2005;34:461–465
  15. Pringsheim T, Edmeads J. Effective treatment of migraines: Terminating acute attacks, reducing their frequency. Postgraduate Medicine. 2004;115:28–50
  16. Robertson J, Shilkofski N. The Harriet Lane handbook. In: 17th ed.. Philadelphia: Elsevier; 2005;p. 698–1009
  17. Rosenblum RK, Fisher PG. A guide to children with acute and chronic headaches. Pediatric Health Care. 2001;15:229–235
  18. Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache an evidence-based review: Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2000;55:754–762
  19. Tarascon Pocket Pharmacopoeia. Lompoc, CA: Tarascon Publishing; 2007;
  20. Unger J. Pediatric migraine: Clinical pearls in diagnosis and therapy. Consultant for Pediatricians. 2006;5:545–551
  21. U.S. Food and Drug Administration. (2006). Information for healthcare professionals. Selective serotonin reuptake inhibitors (SSRIs), selective serotonin norepinephrine retake inhibitors (SNRLs), 5-Hydroxytrypamine receptor agonists (triptans). FDA Alert. Potentially life-threatening serotonin syndrome with combined use of SSRIs or SNRIs and Triptan medications. Retrieved July 26, 2007, from www.fda.gov/cder/drug/infosheets/HCP/triptansHCP.htm
  22. U.S. Food and Drug Administration. (2007). Antidepressant use in children, adolescents, and adults. Retrieved September 26, 2007, from www.fda.gov/cder/drug/adtidepressants/default.htm

PII: S0891-5245(07)00403-8

doi: 10.1016/j.pedhc.2007.10.009

Journal of Pediatric Health Care
Volume 22, Issue 1 , Pages 52-59 , January 2008

Article Tools